In:
npj Precision Oncology, Springer Science and Business Media LLC, Vol. 5, No. 1 ( 2021-07-14)
Abstract:
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts ( n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10 −10 , OR 3.11, 95% CI 2.2–4.5). Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.
Type of Medium:
Online Resource
ISSN:
2397-768X
DOI:
10.1038/s41698-021-00178-z
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
2891458-2
Bookmarklink